Abstract:Introduction: Nasopharyngeal carcinoma (NPC) originates from the mucous epithelium of the nasopharynx. Although induction chemotherapy plus concurrent chemoradiotherapy is the major therapeutic protocol used for locally advanced NPC without metastasis, more research studies are needed to evaluate the curative effects. We aim to identify the therapeutic effects and prognosis after induction chemotherapy plus concurrent chemoradiotherapy in the treatment of locally advanced NPC under the intensity-modulated radiotherapy mode. Methods: The patients ( N = 544) with locally advanced NPC (III and Iva, UICC 8th) after intensity-modulated radiotherapy with induction chemotherapy and concurrent chemoradiotherapy were included in this study. We analyzed the characteristics of patients including gender, age, smoking status, tumor node staging system, clinical stage, pathological type, the therapy protocol of induction chemotherapy and concurrent chemoradiotherapy, and chemotherapy prescription. Results: We have found the 5-year survival rates of overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) were 85.21%, 78.51%, 90.71%, and 85.21% in follow-up, and these data indicated that our therapeutic procedure provided beneficial effects on survival rates. Subsequently, the chemotherapy drug based on docetaxel (DOC) provided a more beneficial effect on survival rate compared with taxol (TXT) (all estimated HR >1; p = 0.005, 0.004, and <0.001 of OS, PFS, and DMFS), but there was no significant difference between chemotherapy drugs based on cisplatin (DDP) and nedaplatin (NDP) in treating NPC patients ( p = 0.390, 0.549, 0.364, and 0.645 of OS, PFS, LRRFS, and DMFS). The therapeutic effects of induction chemotherapy revealed no difference between TPF and TP (T: DOC or TXT, P: DDP or NDP, and F: 5-fluorouracil) ( p = 0.541, 0.897, 0.498, and 0.765 of OS, PFS, LRRFS, and DMFS). In addition, there was also no significant change between concurrent chemotherapy with TP dual drugs or a single platinum drug (being excluded in the multivariate model using forward [Wald] procedure). Moreover, the survival rate showed no difference between platinum accumulation dose of more or less than 150 mg/m 2 for concurrent chemotherapy (being excluded in the multivariate model using forward [Wald] procedure). Conclusion: Our results indicate that induction chemotherapy plus concurrent chemoradiotherapy under intensity-modulated radiotherapy which is the standard therapeutic method for locally advanced NPC provides beneficial therapeutic effects, and it is worthy of further study.

Long-term Efficacy of Induction Chemotherapy Plus Concurrent Radiochemotherapy on Advanced Nasopharyngeal Carcinoma

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy Versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Retrospective Analysis

Induction-concurrent Chemoradiotherapy Versus Induction Chemotherapy and Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Comparison of efficacy of induction chemotherapy plus intensi-ty-modulated radiotherapy and concurrent chemo-radiotherapy plus adjuvant chemotherapy for patients with loco-regionally ad-vanced nasopharyngeal carcinoma

[A comparative study of long-term effects between induction chemotherapy and concurrent chemotherapy on patients with local advanced nasopharyngeal carcinoma]

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy

Long-term Outcomes of Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy and Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients with N3 Disease

Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up

Survival Benefit Of Adding Chemotherapy To Intensity Modulated Radiation In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Comparison of the Short-Term Efficacy Between Docetaxel Plus Carboplatin and 5-Fluorouracil Plus Carboplatin in Locoregionally Advanced Nasopharyngeal Carcinoma.

Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma

Impact of Chemotherapy Compliance on the Therapeutic Efficacy of Patients with Locally Advanced Nasopharyngeal Carcinoma

Induction Chemotherapy Combined with Intensity-Modulated Radiotherapy for 129 Nasopharyngeal Carcinoma Patients with Synchronous Metastases: A Retrospective Study

Five-year Efficacy Analysis of PF Chemotherapy Combined with Radiotherapy in Patients with Local-Advanced Nasopharyngeal Carcinoma

Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma

Induction chemotherapy followed by radiotherapy and adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma treated